Compare WKSP & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKSP | ALLR |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 16.3M |
| IPO Year | N/A | N/A |
| Metric | WKSP | ALLR |
|---|---|---|
| Price | $2.24 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 250.3K | 155.7K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,286,679.00 | N/A |
| Revenue This Year | $142.95 | N/A |
| Revenue Next Year | $109.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 123.37 | N/A |
| 52 Week Low | $1.92 | $0.61 |
| 52 Week High | $12.00 | $2.35 |
| Indicator | WKSP | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 50.30 |
| Support Level | $2.10 | $0.97 |
| Resistance Level | $2.42 | $1.18 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.82 | 69.02 |
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.